Alprostadil
Alprostadil, Caverject, Edex, Prostin (alprostadil) is a small molecule pharmaceutical. Alprostadil was first approved as Prostin vr pediatric on 1982-01-01. It is used to treat aortic arch syndromes, aortic coarctation, hypoplastic left heart syndrome, patent ductus arteriosus, and pulmonary hypertension amongst others in the USA. The pharmaceutical is active against prostaglandin E2 receptor EP1 subtype and prostaglandin E2 receptor EP2 subtype. In addition, it is known to target prostaglandin E2 receptor EP3 subtype, cation channel sperm-associated protein 1, prostacyclin receptor, cation channel sperm-associated protein 2, cation channel sperm-associated protein 4, cation channel sperm-associated protein 3, prostaglandin E2 receptor EP4 subtype, and prostaglandin D2 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Alprostadil, Caverject, Edex, Prostin (discontinued: Caverject, Edex, Muse)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alprostadil | ANDA | 2024-06-04 |
| caverject | New Drug Application | 2024-05-13 |
| caverject impulse | New Drug Application | 2024-07-23 |
| edex | New Drug Application | 2024-03-27 |
| prostin | New Drug Application | 2022-10-03 |
| prostin vr pediatric | 2006-04-20 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01E: Other cardiac preparations in atc
— C01EA: Prostaglandin cardiac therapy preparations
— C01EA01: Alprostadil
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04B: Urologicals
— G04BE: Drugs used in erectile dysfunction
— G04BE01: Alprostadil
HCPCS
Code | Description |
|---|---|
| J0270 | Injection, alprostadil, 1.25 mcg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
| J0275 | Alprostadil urethral suppository (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
Clinical
Clinical Trials
169 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 2 | 3 | 2 | 1 | 5 | 12 |
| Induced labor | D007751 | — | — | — | 1 | 3 | 3 | 5 | 12 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 1 | 2 | 2 | 1 | 6 |
| Obstetric labor complications | D007744 | — | — | — | 2 | 1 | 2 | 1 | 5 |
| Premature rupture fetal membranes | D005322 | HP_0001788 | O42 | — | — | — | 3 | 2 | 5 |
| Rupture | D012421 | — | — | — | — | — | 3 | 2 | 5 |
| Cervical ripening | D020070 | — | — | — | 1 | 2 | 1 | 1 | 5 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | — | 1 | 1 | 1 | 4 |
| Ischemia | D007511 | EFO_0000556 | — | — | 2 | — | 1 | 1 | 4 |
| Arterial occlusive diseases | D001157 | EFO_0009085 | — | 1 | 1 | 1 | 1 | — | 4 |
Show 39 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 3 | 1 | — | 2 | 6 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | — | 3 | 1 | — | 2 | 6 |
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | 1 | — | 2 | 4 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 1 | — | 1 | 2 |
| Leiomyoma | D007889 | HP_0000131 | D25 | — | 1 | 2 | — | — | 2 |
| Myofibroma | D047708 | — | — | — | 1 | 2 | — | — | 2 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | 1 | — | 1 | 2 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 1 | — | — | 1 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | — | 1 | — | — | 1 |
| Transient tachypnea of the newborn | D059245 | — | P22.1 | — | — | 1 | — | — | 1 |
Show 11 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | — | — | 1 | — | — | 2 | 3 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | 2 | — | — | 1 | 3 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | 1 | — | — | 1 | 2 |
| Acute lung injury | D055371 | EFO_0004610 | — | — | 1 | — | — | 1 | 2 |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | — | 1 | — | — | 1 | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | — | 1 | 2 |
| Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | 2 | 2 | — | — | — | 2 |
| Chronic chemical and drug induced liver injury | D056487 | EFO_1000905 | — | 2 | 2 | — | — | — | 2 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | 2 | — | — | — | 2 |
| Physiological sexual dysfunction | D012735 | — | — | 1 | 1 | — | — | — | 2 |
Show 23 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | — | — | — | 1 | 2 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | 1 | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | — | — | — | — | 2 |
| Vasculogenic impotence | D018783 | EFO_1001234 | — | 1 | — | — | — | — | 1 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 1 | — | — | — | — | 1 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | — | — | — | — | 1 |
| Retained placenta | D018457 | — | O72.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | — | — | — | — | 2 | 2 |
| Psychological stress | D013315 | — | — | — | — | — | — | 2 | 2 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | — | 2 | 2 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | — | 2 | 2 |
| Traumatic stress disorders | D040921 | — | — | — | — | — | — | 2 | 2 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | — | — | 2 | 2 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 2 | 2 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 2 | 2 |
| Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 2 | 2 |
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | — | 2 | 2 |
Show 62 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Alprostadil |
| INN | alprostadil |
| Description | Prostaglandin E1 is a prostaglandins E. It has a role as a platelet aggregation inhibitor, a vasodilator agent, an anticoagulant and a human metabolite. It is a conjugate acid of a prostaglandin E1(1-). |
| Classification | Small molecule |
| Drug class | vasodilators (undefined group); prostaglandins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 745-65-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL495 |
| ChEBI ID | 15544 |
| PubChem CID | 5280723 |
| DrugBank | DB00770 |
| UNII ID | F5TD010360 (ChemIDplus, GSRS) |
Target
Agency Approved
PTGER1
PTGER1
PTGER2
PTGER2
Organism
Homo sapiens
Gene name
PTGER1
Gene synonyms
NCBI Gene ID
Protein name
prostaglandin E2 receptor EP1 subtype
Protein synonyms
PGE receptor, EP1 subtype, PGE2 receptor EP1 subtype, prostaglandin E receptor 1 (subtype EP1), 42kD, prostaglandin E receptor 1 (subtype EP1), 42kDa, prostaglandin E receptor 1, subtype EP1, Prostanoid EP1 receptor
Uniprot ID
Mouse ortholog
Ptger1 (19216)
prostaglandin E2 receptor EP1 subtype (P35375)
Alternate
PTGER3
PTGER3
CATSPER1
CATSPER1
PTGIR
PTGIR
CATSPER2
CATSPER2
CATSPER4
CATSPER4
CATSPER3
CATSPER3
PTGER4
PTGER4
PTGDR
PTGDR
Organism
Homo sapiens
Gene name
PTGER3
Gene synonyms
NCBI Gene ID
Protein name
prostaglandin E2 receptor EP3 subtype
Protein synonyms
PGE receptor, EP3 subtype, PGE2 receptor EP3 subtype, PGE2-R, prostaglandin E receptor 3 (subtype EP3), prostaglandin receptor (PGE-2), Prostanoid EP3 receptor
Uniprot ID
Mouse ortholog
Ptger3 (19218)
prostaglandin E2 receptor EP3 subtype (P30557)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Edex – Auxilium Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Alprostadil
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 22,381 documents
View more details
Safety
Black-box Warning
Black-box warning for: Alprostadil, Prostin, Prostin vr pediatric
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
86,528 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use